Direct Answer
Managed care organizations (MCOs) administer health insurance benefits for employer-sponsored plans, Medicaid managed care, Medicare Advantage, and individual/exchange plans, generating revenue from premiums paid by employers, government programs, and individuals. The major publicly traded MCOs are UnitedHealth Group (the largest by revenue, with both the UnitedHealthcare insurance business and the Optum health services platform), CVS Health/Aetna (insurance combined with retail pharmacy and pharmacy benefit management), Cigna (commercial insurance and Evernorth health services including Express Scripts PBM), Humana (disproportionately Medicare Advantage-focused), Centene (Medicaid managed care dominant), and Molina Healthcare (Medicaid/CHIP). Key metrics are the medical loss ratio (MLR: medical costs as % of premium revenue; lower is better for profitability), premium revenue growth, and the growth and margins of integrated health services businesses.
Managed Care Business Model: Premium Underwriting and MLR Management
Premium underwriting and actuarial risk: MCOs earn premiums from employers, the federal government (for Medicare Advantage and Medicare Part D plans), and state Medicaid programs, and pay out medical claims on behalf of enrolled members. The financial model is essentially actuarial: the MCO must price premiums accurately enough to cover expected medical costs (the medical loss ratio, typically 80-87%) plus administrative expenses (SG&A: 10-15% of premiums) while generating an operating margin (typically 5-8% for well-run commercial MCOs; varies significantly for government programs). The underwriting cycle: commercial group health insurance (employer-sponsored) is repriced annually at renewal. MCOs analyze prior-year claims experience for each employer group, project medical cost trends (utilization trends + unit cost trends = medical cost trend, typically 5-8% per year), and set premium rates. A disciplined MCO prices each renewal to achieve its target MLR; an aggressively growing MCO may underprice to win new business, running higher-than-expected MLRs until the book seasons and rates can be corrected. The ACA (Affordable Care Act) mandated minimum MLRs (80% for individual/small group, 85% for large group) that require MCOs to rebate excess premiums to enrollees if actual MLRs fall below these thresholds, placing a floor under value delivery.
Medicare Advantage (MA): the most important growth driver: Medicare Advantage is the private alternative to traditional Medicare (Parts A and B), in which beneficiaries choose a private health plan that receives a risk-adjusted capitation payment from CMS (Centers for Medicare & Medicaid Services) in lieu of traditional fee-for-service Medicare coverage. MA plans enrolled approximately 32 million beneficiaries as of 2024, roughly half of all Medicare-eligible adults, up from approximately 13 million in 2010. The appeal for beneficiaries: MA plans typically offer dental, vision, and hearing benefits that traditional Medicare doesn't cover, plus drug coverage (Part D), with coordinated care management and often lower out-of-pocket costs. For MCOs, MA is structurally attractive because CMS's risk adjustment model (the hierarchical condition category, or HCC, model) pays higher rates for sicker members, aligning MCO incentives with actually managing care for high-cost beneficiaries. An MCO that can accurately code member diagnoses (capturing all HCC codes that legitimately apply) receives higher risk adjustment revenue, and one that manages care efficiently (preventing unnecessary hospitalizations, coordinating chronic disease management) generates higher margins. The risk: CMS periodically revises its risk adjustment model (as it did significantly in 2024, reducing risk scores for many MA plans), creating revenue headwinds that are difficult to anticipate until regulatory announcements. Humana, which derives approximately 80%+ of revenue from Medicare Advantage, is the most exposed to MA pricing/risk adjustment changes.
Vertical integration into health services: The largest MCOs have vertically integrated into adjacent health services businesses that generate earnings less sensitive to MLR volatility than pure insurance underwriting. UnitedHealth Group's Optum segment (approximately 40% of total earnings) provides pharmacy benefit management (OptumRx), health data analytics and technology services (OptumInsight), and direct care delivery (OptumHealth, which operates care clinics and home health services). CVS Health combines its retail pharmacy, pharmacy benefit management (Caremark), and Aetna insurance businesses. Cigna's Evernorth segment (Express Scripts PBM) generates approximately 40% of segment earnings. These PBM and health services businesses generate fee-for-service or cost-plus revenue that does not carry insurance underwriting risk and is therefore more stable and predictable than premium-based insurance revenue. The vertical integration also creates a potential competitive advantage in care management: an MCO that owns both the insurance plan and the care delivery infrastructure can coordinate patient care more effectively, potentially improving health outcomes and reducing costs in ways that a pure insurance company cannot. The same integration creates a regulatory risk: the FTC has scrutinized vertical integration in healthcare (particularly PBM-MCO combinations) as potentially anticompetitive, and legislative proposals to separate PBM and insurer operations could structurally disrupt these integrated models.
Key Metrics to Track
| Metric | What It Measures | Benchmark Context |
|---|---|---|
| Medical Loss Ratio (MLR) | Medical costs / premium revenue; profitability core metric | Commercial: target 82-85%; Medicare Advantage: target 85-88%; Medicaid: 88-92%; above-guidance MLR = claims surprise or underpricing; watch for seasonality (Q1 typically lowest utilization, Q4 highest) and normalization after COVID utilization suppression reversed 2022-2024 |
| Premium Revenue Growth | Top-line health plan growth; membership x premium rate | Target 8-12% annually driven by membership growth + medical cost trend pricing; MA membership growth: 8-10% annually; commercial membership: 2-4%; watch MA star ratings (CMS quality stars determine bonuses: a 4-star plan vs. 3.5-star receives ~5% higher capitation) |
| Medicare Advantage Membership and Star Ratings | Government program scale; quality bonus eligibility | UnitedHealthcare MA: ~8M members (largest); Humana: ~6M (highest revenue concentration); Star ratings: 4+ stars = bonus payments; watch annual CMS star rating announcement (Oct each year) for next year's bonus eligibility; rating decline = revenue headwind 2 years forward |
| Optum / Evernorth Revenue and Margin | Health services diversification; non-insurance earnings quality | Optum: ~40% of UNH earnings, targeting 10-13% operating margin; Evernorth: 35-40% of Cigna earnings; growth in health services earnings reduces insurance underwriting volatility; track pharmacy scripts managed and care clinic visit volumes |
| Operating Cost Ratio (SG&A / Premium) | Administrative efficiency | Best-in-class MCOs: 8-10% SG&A/premium; technology investment (AI claims processing, care management platforms) should improve ratio over time; watch for sudden cost ratio increases signaling integration problems after acquisitions |
| Days Claims Payable (DCP) | Claims payment speed; reserve adequacy indicator | Target 40-50 days; rising DCP = building reserves (conservative) or claims backlog; falling DCP = paying claims faster or releasing reserves; MCOs manage DCP to signal reserve strength without over-reserving and suppressing current earnings |
Principal Risks
- CMS Medicare Advantage rate and risk adjustment changes: CMS sets the rates it pays to MA plans annually through the "advance notice" and "final rate" process. When CMS reduces MA rates or recalibrates the risk adjustment model (as it did with the V28 HCC model transition announced in 2023, phasing in lower risk scores that reduced MA plan capitation), MCOs with high MA revenue concentration face earnings headwinds that can persist for multiple years. Humana, with approximately 80%+ of revenue from MA, is most exposed; UnitedHealth and Aetna have more diversified revenue but still feel significant impacts from MA rate changes. The political economy: MA plans are popular with beneficiaries (higher benefits than traditional Medicare), so outright rate cuts are politically unpopular, but CMS periodically recalibrates risk adjustment to address concerns about risk score "inflation" (MCOs submitting more HCC codes to receive higher risk-adjusted payments), creating recurring earnings headwinds.
- Unexpected medical cost trends (MLR surprises): Medical cost trends are inherently difficult to predict: new high-cost treatments (GLP-1 obesity drugs, cell and gene therapies, CAR-T cancer therapies) can create unexpected claims spikes, behavioral health demand can shift as utilization awareness grows, and post-pandemic deferred care catch-up effects create utilization surges that are difficult to anticipate in advance. When actual medical costs exceed pricing assumptions, MCO earnings miss guidance and often miss multiple consecutive quarters as the claims season takes time to fully develop. The 2022-2024 period saw elevated medical costs from post-COVID utilization normalization that caught several MCOs underpriced relative to their incurred claims, with Humana most publicly visible in guiding to MLR deterioration.
- Regulatory and legislative risk: MCOs operate under extensive regulation at federal (ACA, Medicare Advantage rules, ERISA for employer plans) and state (insurance premium regulation, benefit mandate laws) levels. The Inflation Reduction Act's Medicare drug price negotiation provisions, ongoing legislative scrutiny of PBM practices, and Congressional proposals to limit MA plan profits or require higher benefit minimums all create regulatory uncertainty. Single-payer healthcare proposals (Medicare for All) represent a tail risk that would fundamentally restructure the private health insurance market, though political feasibility has been low in recent legislative sessions.
Managed Care Analysis Guides
FAQ
What is the medical loss ratio and how does it affect MCO profitability?
The medical loss ratio (MLR) is the percentage of premium revenue that a managed care organization spends on medical claims and quality improvement activities, expressed as: MLR = (Medical Costs + Quality Improvement Expenses) / Premium Revenue. It is the single most important profitability metric for health insurance companies because it directly measures the margin between what the MCO collects in premiums and what it pays out in claims. A lower MLR means more premium revenue falls to operating income; a higher MLR means claims are consuming a larger share of revenue. For a large commercial MCO targeting an 84% MLR on $100 billion in premium revenue, each 100 basis point MLR improvement (from 84% to 83%) generates $1 billion in additional operating income. Conversely, an unexpected 100 bps deterioration (actual claims 1 percentage point above pricing assumptions) costs $1 billion in earnings. The ACA established minimum MLR floors: 80% for individual and small group plans, 85% for large group plans, with rebates to enrollees when actual MLRs fall below these minimums. This creates an unusual dynamic where a very low MLR (below 80-85%) triggers mandatory premium rebates, meaning MCOs cannot indefinitely extract increasing margins through very low loss ratios -- there is a regulatory floor on how favorable the ratio can be from a pure profitability standpoint. Medicare Advantage MLRs are typically higher (85-88%) than commercial because MA plans serve older, sicker populations with higher claim rates, but the higher risk-adjusted premium rates from CMS compensate. Medicaid managed care MLRs are the highest (88-92%) because state contracts often specify MLR floors as a condition of the contract, limiting the profit margin available to the MCO.
Why is Medicare Advantage more profitable than traditional Medicare from an investor perspective?
Medicare Advantage plans generate higher risk-adjusted returns for MCOs than traditional fee-for-service Medicare because the MA model aligns financial incentives with care quality in ways that the traditional Medicare system does not. The core advantage: CMS pays MA plans a capitation (per-member-per-month) rate based on the enrollee's risk score, set to approximate what CMS would have paid for that member under traditional Medicare, with a 2-5% discount to generate savings for the government. MA plans that can deliver equivalent or better health outcomes at costs below the capitation rate retain the difference as profit. The care management opportunity: MA plans can invest in disease management programs, care coordination, preventive services, and social determinants of health interventions that reduce costly hospitalizations. An MA plan that invests $500/year per diabetic member in care management (nutrition counseling, medication adherence support, regular A1C monitoring) and prevents one $15,000 hospitalization per year in 5% of its diabetic members generates $750 in savings per diabetic member, a 50% return on the care management investment. Traditional Medicare fee-for-service has no such incentive structure: physicians are paid per service, not per outcome, creating perverse incentives. Benefit attractiveness driving enrollment: MA plans offer richer benefits (dental, vision, hearing, fitness, over-the-counter drug allowances) than traditional Medicare by using their managed care efficiencies to fund additional benefits while maintaining a positive margin. These richer benefits attract healthier-than-average Medicare beneficiaries (adverse selection concern) while generating higher enrollee satisfaction (MA star ratings) that qualify plans for CMS bonus payments. The bonus pool for 4-star and 5-star MA plans represents approximately $10-15 billion annually industry-wide, creating significant financial incentive to invest in quality improvement measures that drive star ratings.
How does UnitedHealth Group's Optum change its investment profile?
UnitedHealth Group's Optum segment transforms it from a pure-play health insurer into a vertically integrated health services company, substantially changing its revenue quality, earnings stability, and growth profile in ways that justify a premium multiple relative to pure MCO competitors. Optum consists of three businesses: OptumHealth (care delivery -- physician practices, surgery centers, home health, behavioral health services; 60,000+ employed/affiliated physicians), OptumInsight (health data analytics, technology services, and revenue cycle management; serves hospital systems, government agencies, and other MCOs), and OptumRx (pharmacy benefit management; processes approximately 1.5 billion prescriptions annually). The investment profile change: OptumRx generates fee-per-prescription revenue that is independent of UnitedHealthcare's insurance underwriting results -- it earns fees whether or not medical claims trends are favorable. OptumInsight's technology contracts with external health systems are multi-year, predictable, and grow with healthcare system complexity. OptumHealth's value-based care arrangements generate revenue tied to patient panel management and outcome quality, not individual service fee-for-service. Together, Optum now contributes approximately 40-45% of UNH's total operating earnings, making roughly half the company's earnings structurally independent of insurance underwriting volatility. The practical consequence: when MCO peers see significant EPS volatility from MLR surprises (as Humana did in 2023-2024), UnitedHealth's Optum earnings buffer the overall EPS impact, creating more consistent earnings compounding. The market assigns a higher multiple to UNH vs. pure-play MCOs for this reason. The risk of the integrated model: the FTC and DOJ have scrutinized whether dominant MCO-provider-PBM combinations are anticompetitive; potential regulatory requirements to divest or ring-fence Optum from UnitedHealthcare would reduce the integration benefits and the earnings diversification that justify the premium multiple.
What are CMS star ratings for Medicare Advantage and why do they matter?
CMS (Centers for Medicare and Medicaid Services) assigns annual quality star ratings on a 1-to-5 scale to every Medicare Advantage plan, measuring plan performance across approximately 40 quality measures covering preventive care, chronic disease management, member satisfaction, and customer service. Star ratings are publicly reported and used by Medicare beneficiaries to compare plan quality when selecting coverage. For MCOs, star ratings have direct financial consequences through CMS quality bonus payments. Plans rated 4 stars or higher receive quality bonus payments of approximately 5% added to their base benchmark rates; in 2025, this bonus pool was estimated at approximately $12-15 billion industry-wide. A large MA plan with $10 billion in CMS capitation revenue earns approximately $500 million in additional annual revenue from maintaining 4-star status vs. losing it and falling to 3.5 stars. The star rating process: CMS measures performance on HEDIS clinical quality metrics (breast cancer screening rates, diabetes HbA1c control, statin use, blood pressure control), CAHPS member experience surveys (plan responsiveness, access to care, information quality), and HOS health outcomes surveys. Ratings are announced each October and take effect two years later (2024 star ratings affect 2026 payment rates). The two-year lag means MCOs have a limited window to invest in quality improvement after seeing ratings and before the financial impact is realized. Star rating management has become a core competency for MA-focused MCOs: Humana and UnitedHealthcare maintain large quality improvement teams specifically dedicated to closing care gaps (identifying members overdue for preventive screenings and outreaching to schedule them), improving medication adherence rates, and member experience survey optimization.
How do PBMs like CVS Caremark and Express Scripts earn money within managed care?
Pharmacy Benefit Managers (PBMs) are intermediaries between health plan sponsors (employers, MCOs, government programs), retail pharmacies, and pharmaceutical manufacturers. Understanding PBM economics is essential to analyzing CVS Health (Caremark), Cigna (Evernorth/Express Scripts), and UnitedHealth (OptumRx). PBMs earn revenue through three main sources. Spread pricing: in traditional spread-based contracts, the PBM reimburses pharmacies less for a prescription than it charges the health plan sponsor, keeping the difference ("spread"). A PBM might reimburse a pharmacy $25 for a generic and bill the plan sponsor $32, keeping $7 in spread. Pass-through contracts (where the PBM passes the actual pharmacy cost to the plan sponsor and charges a per-claim administrative fee) have grown as large employers demand transparency, but spread-based contracts remain common for smaller plan sponsors. Manufacturer rebates: PBMs negotiate rebates from pharmaceutical manufacturers in exchange for placing branded drugs on favorable formulary positions (tier 1 or tier 2 co-pay vs. tier 3). These rebates, which can total $50-100+ billion industry-wide annually, are partially passed through to plan sponsors (most PBMs now pass 85-100% of rebates to large employer clients who demand it) and partially retained by the PBM. The retained rebate share has been under regulatory and legislative pressure, with the HHS rebate rule attempting to eliminate rebates in Medicare Part D and shift manufacturer discounts to point-of-sale discounts. Specialty pharmacy dispensing: PBMs own specialty mail-order pharmacies (CVS Specialty, Accredo/Express Scripts Specialty) that dispense high-cost specialty drugs (oncology, rheumatology, rare disease biologics), earning dispensing margins that are substantially higher on specialty drugs than on commodity generics. Specialty drugs now represent approximately 50%+ of total drug spend despite being a small percentage of prescription volume, making specialty pharmacy operations the highest-margin component of PBM revenue.
References
- CMS (Centers for Medicare and Medicaid Services): Medicare Advantage enrollment and star ratings data (cms.gov)
- KFF (Kaiser Family Foundation): Health insurance market data, employer survey, ACA enrollment data (kff.org)
- AHIP (America's Health Insurance Plans): Industry statistics and regulatory reports (ahip.org)